INSTITUTO-COORDENADAS
13.10.2020 12:46:08 CEST | Business Wire | Press release
Barcelona’s efforts to become a safe destination for tourists have meant that, of all of Europe’s main tourism destinations, the city and its surrounding areas have been ranked as one of most committed to health safety matters. Monitoring and advice, alongside the involvement of the tourism sector’s main actors, have provided Barcelona with international acknowledgment that will benefit the sector’s recovery. Those are the main conclusions of an ongoing study by Institute Coordenadas into the impact of Covid-19 on the tourism industry.
One of the key indicators that place Barcelona at the forefront for safe spaces internationally is the backing for the city from the World Travel and Tourism Council (WTTC), which has launched a global quality stamp for tourist destinations that provided the strongest guarantees that their public spaces are Covid-secure. Barcelona is a member of the elite group of major European cities that safely welcome a high number of tourists. As such, the city is striving to provide the safest conditions for visitors, around 28 million of whom come to the Catalan capital every year, joining its population of just over 1.6 million. Seville was also acknowledged by the WTTC, along with other destinations in Portugal, Saudi Arabia and Cancun, Mexico.
Barcelona’s seventh position (and the title of top-ranked Spanish city) in the Saffron City Brand Barometer 2020 of the cities with the strongest tourism brands is also a key factor. Similarly, the Global Safe Site certification from Bureau Veritas highlights strict compliance with hygiene and safety measures in Barcelona, which was also the first Spanish city to be awarded the distinction. Key tourist infrastructure such as Park Güell, the city’s zoo and the Tibidabo amusement park have all been awarded the Safe Tourism Certified distinction by the Institute for Spanish Tourism Quality (ICTE), which marks the implementation of a specific Covid-19 risk prevention system. Furthermore, Barcelona has been Biosphere-certified since 2011 as an urban destination committed to sustainability.
The website promoted by Barcelona City Council as part of the Barcelona Safe City/Safe Visit initiative is a key element in the process of getting the city moving again post-Covid. The portal can be used by companies and professionals to check the information related to their respective fields and for obtaining a personalised report featuring all the necessary elements to ensure protocols adapt to maximum safety requirements.
The involvement of actors from different municipal levels has been one of the factors that has allowed Barcelona to compete to become a safer city in terms of health. The Safe City initiative included an interdisciplinary working group with members from the Catalan Directorate of Tourism, the Public Health Agency of Catalonia, the Municipal Civil Defence Service, the Guàrdia Urbana municipal police force, BCNecologia/Barcelona Urban Ecology Agency, the city’s Department of Commerce, its Culture Institute and the Barcelona Sports Institute, municipal company B:SM, trade fair organisation Fira de Barcelona, the Turisme de Barcelona Consortium and ISGlobal.
Another aspect that will improve safety features for tourists in Barcelona is the introduction of the app currently being put together by the Turisme de Barcelona Consortium and Barcelona City Council. The app will allow users to check on health recommendations and the situation at visitor locations, so as to avoid crowds and queueing. The app’s initial launch phase will feature opening times and entry points for the most popular tourist destinations, along with guidance for health and mobility. Plans for the second phase include real-time information and the option of booking ahead to ensure safer management of tourist activities. The app is being developed by Eurecat Technology Centre in collaboration with the Mobile World Capital Barcelona Foundation and Barcelona Tech City.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
